Merck reports Phase III myeloma data for Zolinza
This article was originally published in Scrip
Executive Summary
Merck & Co has reported that a Phase III study investigating Zolinza (vorinostat), in combination with bortezomib, in patients with progressive multiple myeloma has met its primary endpoint of improved progression-free survival (PFS) in patients with relapsed and/or refractory forms of the disease.